Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)

Sponsor
University Hospital, Bordeaux
Study ID
NCT05839717
Status
Recruiting
Apply to this trial

Conditions

  • Myeloproliferative Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Blood sampling — PROCEDURE
    A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice

Study Details

Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.

Key Dates

First listed
May 3, 2023
Start date
Jun 19, 2023
Status verified
Dec 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: PV and ET patients
    The cohort will be composed of PV and ET patients, some with a history of thrombosis and some without any history of thrombosis. A comparison will also be performed between patients with different MPN (PV or ET) and the type of thrombosis (venous, arterial, splanchnic)

Primary Outcome Measure

History of thrombosis at MPN diagnosis [ Time Frame: At inclusion ]

Central Contacts

Related Studies